Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study
Investigational New Drugs · 2025
DOI: 10.1007/s10637-024-01502-7 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Investigational New Drugs, 2025. Verfasst von Zeyu Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing M…. Hauptthemen laut MEDLINE: Phenylurea Compounds, Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: The combination therapy of lenvatinib and immunotherapy as first-line treatment remains controversial in unresectable hepatocellular carcinoma (uHCC). This research aimed to compare the efficacy and safety of lenvatinib monotherapy (L) and combination therapy of lenvatinib and immune checkpoint inhibitor (LI) in lenvatinib-insensitive patients with uHCC. METHODS: Two hundred fifty-five uHCC patients were enrolled in this study. Patients were classified into two groups: (1) Lenvatinib monotherapy (L); (2) Combination therapy (LI). Patients who remained stable disease (SD) but did not achieve complete response (CR) or partial response (PR) or progression disease (PD) for at least 3 months after receiving lenvatinib monotherapy were defined as lenvatinib-insensitive. Overall survival (OS) and progression-free survival (PFS), baseline characteristics, and safety were compared between groups. RESULTS: The LI group had longer OS (15.9 months vs. 11.9 months, P = 0.001) and PFS (12.6 months vs. 7.3 months, P < 0.001) than the L group. ECOG PS was an independent prognostic factor affecting OS and Up-to-seven was an independent prognostic factor affecting PFS. The frequency of grade ≥ 3 treatment-related adverse events (TRAEs) was not significantly different. CONCLUSIONS: Our study demonstrated that the combination therapy (LI) had longer OS and PFS than the lenvatinib monotherapy (L) in lenvatinib-insensitive patients with uHCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
- Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. xqy1984king@njmu.…
- Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. jsnjygw@njmu.edu.…
Zitieren
APA
Yu, Z., Leng, B., You, R., Wang, C., Diao, L., Xu, Q., & Yin, G. (2025). Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01502-7
Vancouver
Yu Z, Leng B, You R, Wang C, Diao L, Xu Q, et al. Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study. Investigational New Drugs. 2025. doi:10.1007/s10637-024-01502-7
BibTeX
@article{Yu2025,
author = {Yu, Zeyu and Leng, Bin and You, Ran and Wang, Chendong and Diao, Lingfeng and Xu, Qingyu and Yin, Guowen},
title = {Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study},
journal = {Investigational New Drugs},
year = {2025},
doi = {10.1007/s10637-024-01502-7}
}
EUVIMED